Skip to main content

Revvity Q3 FY2026 results

  • RVTY · NYSE
  • Instruments
  • Health Care Equipment
  • S&P 500
$154.39−1.67%Close 13 Nov 2026 · Market value $16.71B

Revvity reported revenue of $729 million, up 4.3% from a year earlier, net income of $62.3 million and diluted earnings per share of $0.56 against $0.40 for the third quarter of fiscal 2026 (the three months to 4 Oct 2026).

From its quarterly report, the results first announced on 3 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 4 Oct 2026, against the three months to 28 Sep 2025. Amounts in USD.

Revvity Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$728.9M$698.9M+4.3%
Gross profit$418.6M$374.6M+11.7%
Gross margin57.4%53.6%+3.8 pts
Operating income$95.14M$81.90M+16.2%
Operating margin13.1%11.7%+1.3 pts
Net income$62.30M$46.65M+33.5%
Diluted EPS$0.56$0.40+40.0%
Operating cash flow$166.7M$138.5M+20.4%
Capital expenditure$14.35M$18.50M−22.5%
Free cash flow$152.4M$120.0M+27.0%

Operating KPIs for the quarter

Revvity operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Product revenue$596.8Mup 4.1%
Service revenue$132.1Mup 5.1%
Life Sciences revenue$379.6Mup 10.7%
Diagnostics revenue$349.3Mdown 1.9%
Americas revenue$341.9Mup 11.3%
Europe revenue$220.8Mup 9.1%
Asia revenue$166.2Mdown 12.2%

Earlier quarters

Revvity results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY20264 Oct 2026$728.9M+4.3%$0.56
Q2 FY20265 Jul 2026$729.7M+1.3%$0.47
Q1 FY20265 Apr 2026$711.1M+7.0%$0.36
Q4 FY202528 Dec 2025$772.1M+5.9%$0.87
Q3 FY202528 Sep 2025$698.9M+2.2%$0.40
Q2 FY202529 Jun 2025$720.3M+4.1%$0.46
Q1 FY202530 Mar 2025$664.8M+2.3%$0.35
Q4 FY202429 Dec 2024$729.4M+4.8%$0.78

More on Revvity: financial statements · revenue · earnings per share

RVTY's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.